吸收不良症候群市場規模、佔有率和成長分析：按病因、按診斷工具、按治療方法、按最終用戶、按地區 - 行業預測，2024-2031 年

吸收不良症候群市場規模在 2022 年為 22.9 億美元，從 2023 年的 24.3 億美元成長到 2031 年的 39.4 億美元，預測期間（2024-2031 年）預計將以 6.2% 的複合年成長率成長。

吸收不良症候群包括多種以胃腸道營養吸收受損為特徵的疾病，例如乳糜瀉、克隆氏症和其他胃腸道疾病。由於生活方式的改變、飲食和人口老化，全球吸收不良症候群市場的盛行率不斷增加，推動了對診斷工具和治療方案的需求。診斷技術的進步，例如改進的成像、生物標記的識別和基因檢測，大大提高了吸收不良症候群診斷的速度和準確性，從而可以及時進行醫療干預。此外，患者和醫療保健提供者意識的提高也促進了早期發現和管理。教育工作和資訊傳播使人們能夠識別症狀並接受適當的醫療護理，從而改善結果。

目錄

介紹

• 這項研究的目的
• 定義
• 市場範圍

調查方法

• 資訊採購
• 二手資料來源和主要資料來源
• 市場規模預測
• 市場假設與限制

執行摘要

• 市場概況展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場動態
  • 促進因素
  • 機會
  • 抑制因素
  • 任務
• 波特的分析

吸收不良症候群市場洞察

• 市場生態系統
• 監管環境
• 創新矩陣
• 主要投資分析
• 關鍵成功因素
• 市場魅力指數
• 競爭程度

吸收不良症候群市場：依病因分類

• 市場概況
• 乳糜瀉
• 腸道疾病
• 惠普爾氏症
• 短腸症候群
• 其他

吸收不良症候群市場：依診斷工具分類

• 市場概況
• 影像
  • MRI
  • 電腦斷層掃描
• 驗血
  • 血清營養水平
  • 基因檢測
• 內視鏡檢查
• 切片檢查

吸收不良症候群市場：治療方法

• 市場概況
• 藥品
  • 補充酶
  • 發炎藥
• 膳食食品
  • 維他命
  • 礦物
• 改善飲食習慣
• 手術治療

吸收不良症候群市場：依最終用戶分類

• 市場概況
• 醫院藥房
• 營養診所
• 學術研究所
• 其他

吸收不良症候群市場：按地區

• 市場概況
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲 (MEA)
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲地區

競爭格局

• 前5名企業對比
• 主要企業市場定位（2023年）
• 主要市場參與者所採取的策略
• 近期市集活動
• 主要企業市場佔有率（2023年）

主要企業簡介

• AbbVie Inc.（United States）
• Allergan plc（Ireland）
• Bausch Health Companies Inc.（Canada）
• Bayer AG（Germany）
• Dr. Reddy's Laboratories Ltd.（India）
• GlaxoSmithKline plc（United Kingdom）
• Johnson & Johnson（United States）
• Merck & Co., Inc.（United States）
• Mylan NV（Netherlands）
• Novartis AG（Switzerland）
• Pfizer Inc.（United States）
• Roche Holding AG（Switzerland）
• Sanofi SA（France）
• Takeda Pharmaceutical Company Limited（Japan）
• Teva Pharmaceutical Industries Ltd.（Israel）
• AstraZeneca PLC（United Kingdom）
• Eisai Co., Ltd.（Japan）
• Ferring Pharmaceuticals（Switzerland）
• Mallinckrodt Pharmaceuticals（United Kingdom）
• UCB SA（Belgium）

Malabsorption Syndrome Market size was valued at USD 2.29 billion in 2022 and is poised to grow from USD 2.43 billion in 2023 to USD 3.94 billion by 2031, growing at a CAGR of 6.2% during the forecast period (2024-2031).

Malabsorption Syndrome encompasses a range of conditions characterized by impaired nutrient absorption in the gastrointestinal tract, stemming from factors like celiac disease, Crohn's disease, and other gastrointestinal disorders. The global market for Malabsorption Syndrome has seen increased prevalence due to lifestyle changes, dietary habits, and an aging population, driving demand for diagnostic tools and treatment options. Advances in diagnostic technologies, including improved imaging modalities, biomarker identification, and genetic testing, have significantly enhanced the speed and accuracy of Malabsorption Syndrome diagnosis, enabling timely medical interventions. Moreover, heightened awareness among patients and healthcare providers has facilitated early detection and management. Education initiatives and information dissemination have empowered individuals to recognize symptoms and seek appropriate medical care, resulting in improved outcomes.

Top-down and bottom-up approaches were used to estimate and validate the size of the Malabsorption Syndrome market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Malabsorption Syndrome Market Segmental Analysis

The global Malabsorption Syndrome market is segmented based on Causative Diseases, Diagnostic Tools, Treatment Modalities, End-User, and region. Based on Causative Diseases, the market is segmented into Celiac Disease, Crohn's Ailment, Intestinal Disorders, Whipple's Disease, Short Bowel Syndrome, and Others. Based on Diagnostic Tools, the market is segmented into Imaging (MRI, CT scans), Blood Tests (Serum nutrient levels, Genetic testing), Endoscopy & Biopsy. By treatment modalities, the market is segmented into Medications (Enzyme replacement, Anti-inflammatory drugs), Nutritional Supplements (Vitamins, Minerals), Diet Modification, Surgical Interventions. By End-User type, the market is segmented into Hospital Pharmacy, Nutrition Clinics, Academic & Research Institutes, others. Based on region, the market is segmented into North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.

Drivers of the Malabsorption Syndrome Market

Increasing incidence of malabsorption disorders, driven by factors such as evolving lifestyles, dietary patterns, and an aging population, has significantly increased the need for diagnostic and treatment solutions. Advances in diagnostic technology and heightened awareness among healthcare providers and patients have enabled early detection and intervention, positively influencing market growth.

Restraints in the Malabsorption Syndrome Market

One of the primary challenges in the market is the intricate and varied nature of malabsorption disorders, which presents difficulties in accurate diagnosis and tailored treatment. Economic factors, reimbursement challenges, and disparities in healthcare infrastructure across different regions can create obstacles to optimal patient care. Moreover, the high costs associated with advanced diagnostic technologies and specialized treatments may limit accessibility for certain populations, thereby impeding widespread adoption.

Market Trends of the Malabsorption Syndrome Market

There is an increasing focus on personalized medicine, emphasizing the customization of diagnostic and treatment approaches according to individual patient characteristics. This trend aligns with advancements in genetic testing and biomarker identification, enabling more precise and targeted interventions. Additionally, there is a notable movement towards the development of innovative therapeutic approaches, including biologics and gene therapies, demonstrating a continuous commitment to addressing the various causes of malabsorption disorders.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Malabsorption Syndrome Market Insights

• Ecosystem of the Market
• Regulatory Landscape
• Innovation Matrix
• Top Investment Analysis
• Key Success Factor
• Market Attractive Index
• Degree of Competition

Malabsorption Syndrome Market by Causative Diseases

• Market Overview
• Celiac Disease
• Intestinal Disorders
• Whipple's Disease
• Short Bowel Syndrome
• Others

Malabsorption Syndrome Market by Diagnostic Tools

• Market Overview
• Imaging
  • MRI
  • CT scans
• Blood Tests
  • Serum nutrient levels
  • Genetic testing
• Endoscopy
• Biopsy

Malabsorption Syndrome Market by Treatment Modalities

• Market Overview
• Medications
  • Enzyme replacement
  • Anti-inflammatory drugs
• Nutritional Supplements
  • Vitamins
  • Minerals
• Diet Modification
• Surgical Interventions

Malabsorption Syndrome Market by End-User

• Market Overview
• Hospital Pharmacy
• Nutrition Clinics
• Academic & Research Institutes
• Others

Malabsorption Syndrome Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergan plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bausch Health Companies Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eisai Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ferring Pharmaceuticals (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mallinckrodt Pharmaceuticals (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• UCB S.A. (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments